- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03822572
ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer (ABCSG C08)
ABCSG C08 - Exercise II: Randomized Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer
ABCSG C08 is a randomized, two-arm, multicenter trial to investigate the efficacy of endurance exercise following adjuvant chemotherapy in patients with colorectal cancer.
Indication: Locally advanced colorectal cancer after adjuvant chemotherapy. Evidence supporting the beneficial effects of exercise programs during chemotherapy are available, the results across studies are not entirely consistent. Additional studies are needed to determine the optimal content, intensity, and form of training programs.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Colorectal cancer is the second leading cause of cancer mortality in Western countries after breast cancer among women and lung cancer among men. About 5.000 new cases are diagnosed each year in Austria. This represents an annual incidence of 50-60 per 100.000 inhabitants. In patients with colorectal cancer stage III and in certain situations even in stage II adjuvant chemotherapy is indicated after R0 resection. Despite recent advances in adjuvant chemotherapy 20-30% of these patients still relapse. About 80% of recurrences occur in the first three years.
There is consistent evidence from several observational epidemiologic studies that physical activity reduces the risk of developing colon cancer. In recent years several observational studies even showed a reduction in relapse rate, colon cancer-specific mortality and overall mortality by physical activity in patients with colon and breast cancer. Colon cancer survivors who engaged in higher levels of physical activity experienced a 50-60% improvement in long-term outcomes compared to inactive patients. Different mechanisms for the protective effect of physical activity on colon cancer have been proposed and it is believed that the same mechanisms of physical activity are also involved in the improvement of disease outcomes in gastrointestinal cancer survivors. Physical activity leads to decrease of inflammation, decreased levels of insulin-like growth factor (IGF) and insulin, reduced transit time through the gut and increased levels of vitamin D. Factors, that are associated with a reduced risk of colon polyps, colon cancer and colon cancer mortality.
A review on the impact of various exercise programs on fatigue, found good evidence that exercise not only decreased levels of fatigue, but also increased quality of life, mood and functioning.
While there is evidence supporting the beneficial effects of exercise programs during chemotherapy, the results across studies are not entirely consistent. Additional studies are needed to determine the optimal content, intensity, and form of training programs.
Recently ABCSG has investigated the feasibility of endurance exercise after adjuvant chemotherapy in patients with locally advanced colorectal cancer in the investigator's study group (ABCSG C07 Exercise - pilot study). Results concerning compliance of patients have been considered for sample size estimations and study planning.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Martina Putz, PhD
- Phone Number: +43 1 4089230
- Email: martina.putz@abcsg.at
Study Contact Backup
- Name: Aleksandra Mystek, BBSc
- Phone Number: +43 1 4089230
- Email: aleksandra.mystek@abcsg.at
Study Locations
-
-
-
Salzburg, Austria, 5020
- Recruiting
- LKH Salzburg-PMU, UNiv. KLinik f. Innere Med III
-
Contact:
- Richard Greil, MD, Head
-
Principal Investigator:
- Richard Greil, MD, Head
-
-
Styria
-
Graz, Styria, Austria, 8036
- Recruiting
- Med. Univ. Graz
-
Contact:
- Thomas Bauernhofer, MD
-
Principal Investigator:
- Thomas Bauernhofer, MD
-
-
Tyrol
-
Kufstein, Tyrol, Austria, 6330
- Recruiting
- BKH Kufstein
-
Contact:
- August Zabernigg, MD, Head
-
Principal Investigator:
- August Zabernigg, MD, Head
-
-
Upper Austria
-
Braunau Am Inn, Upper Austria, Austria, 5280
- Recruiting
- KH St. Josef Braunau
-
Contact:
- Sigrid Kastl, MD, Head
-
Principal Investigator:
- Sigrid Kastl, MD, Head
-
Linz, Upper Austria, Austria, 4010
- Recruiting
- Hospital BHS Linz, Coop. Study Group
-
Contact:
- Andreas Petzer, MD, Head
-
Principal Investigator:
- Andreas Petzer, MD
-
Linz, Upper Austria, Austria, 4020
- Recruiting
- Kepler Universitätsklinikum Linz
-
Contact:
- Gerhard Hochreiner, MD
-
Principal Investigator:
- Hochreiner, MD
-
Ried, Upper Austria, Austria, 4910
- Withdrawn
- Hospital BHS Ried
-
Steyr, Upper Austria, Austria, 4400
- Recruiting
- State Hospital Steyr
-
Contact:
- Johannes Andel, MD, Head
-
Principal Investigator:
- Johannes Andel, MD, Head
-
Wels, Upper Austria, Austria, 4600
- Recruiting
- Klinikum Wels-Grieskirchen
-
Contact:
- Josef Thaler, MD, Head
-
Principal Investigator:
- Josef Thaler, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- completely resected, histologically confirmed adenocarcinoma of the colon or rectum
- patients, who have completed adjuvant chemotherapy 4-16 weeks prior to randomization
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Age ≥18 years
- adequate hematologic functions <=28d prior to randomization
- able to perform endurance exercise according to protocol
- ability to perform ergometry in order to assess physical capability at the discretion of the investigator
- signed informed consent prior to randomization
Exclusion Criteria:
- significant comorbid conditions precluding participation in a physical activity program (investigators decision)
- disabled patients unable to participate in the physical activity program
- Regular (3-times a week) vigorous physical activity of >150 minutes (type of physical activity: bicycling, cross walking (cross trainer), jogging, walking at a brisk pace, nordic walking, cross country skiing) within the last year before diagnosis of colorectal cancer
- patients unwilling to complete endurance exercise or complete all questionnaires related to the study
- past or current history of other malignant neoplasms other than colorectal cancer in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
- clinically significant cardiovascular disease
- left bundle branch block
- current study with chemotherapy or radiation
- current pregnancy or plans to become pregnant within the next 3 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - endurance exercise
All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan.
The individual pulse-controlled endurance exercise should be performed 3 times a week.
On the basis of age, weight, sex and body fat the normal weight will be calculated.
The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight.
The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise.
Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
|
defined exercise program
|
Other: B - control arm
Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
|
habitual physical activity before the diagnosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoint - disease free survival (DFS)
Time Frame: 8 years (after Last Patient Out (LPO))
|
DFS is defined as the time from randomization to locoregional or metastatic recurrence or the appearance of secondary cancer or death, whichever occurs first.
Recurrence may be either histologically proven or evidenced by imaging via MRI or CT.
Isolated CEA evaluation will not be sufficient to determine a relapse.
|
8 years (after Last Patient Out (LPO))
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy Endpoint I - relapse free survival (RFS)
Time Frame: 8 years (after Last Patient Out (LPO))
|
RFS is defined as the time from randomization to locoregional or metastatic recurrence of colorectal cancer or death, whichever occurs first
|
8 years (after Last Patient Out (LPO))
|
Secondary Efficacy Endpoint II - overall survival (OS)
Time Frame: 8 years (after Last Patient Out (LPO))
|
OS is defined as time from randomization to death from any cause
|
8 years (after Last Patient Out (LPO))
|
Physical Activity Endpoint I - physical activity measured by MET-hours
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of physical activities measured by MET-hours in the domains "work", "leisure time ", "sedentary behavior" and "transporation" by Global Physical Activity Questionnaire (GPAQ) within each study arm and compared between study arms at baseline, at 3, at 6, at 12, at 24 and at 36 months
|
8 years (after Last Patient Out (LPO))
|
Physical Activity Endpoint II - endurance exercise measured by MET-hours
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of endurance exercise measured by MET-hours by pulse-control in arm A at 3, at 6 and at 12 months
|
8 years (after Last Patient Out (LPO))
|
Physical Activity Endpoint III - performance enhancement measured by MET-hours by ergometry
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of performance enhancement measured by MET-hours by ergometry within each study arm (arm A at baseline, at 3, at 6 and at 12 months; arm B at baseline and at 12 months) and compared between study arms at baseline and at 12 months
|
8 years (after Last Patient Out (LPO))
|
Physical Activity Endpoint IV - physical activity measures
Time Frame: 8 years (after Last Patient Out (LPO))
|
Correlation of MET-hours in the domains "work", "leisure time ", "sedentary behavior" and "transporation" by Global Physical Activity Questionnaire (GPAQ) and results of endurance exercise as well as performance enhancement by ergometry (both measured by MET-hours) with DFS, RFS and OS
|
8 years (after Last Patient Out (LPO))
|
Patient Reported Outcome Endpoint I - fatigue
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of fatigue as measured by EORTC - QLQ FATIGUE CAT Theta scores compared between study arms.
Score has no fixed upper and lower limit and a high score represents a high level of fatigue.
|
8 years (after Last Patient Out (LPO))
|
Patient Reported Outcome Endpoint II - emotional functioning score
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the emotional functioning score (based in the functional scale EF) as measured by EORTC QLQ-C30 emotional functioning (based on items) compared between study arms, where a high score for a functional scale represents a high/healthy level of functioning.
|
8 years (after Last Patient Out (LPO))
|
Patient Reported Outcome Endpoint III - physical functioning score
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the standardized physical functioning score (based on the revised functional scale PF2) as measured by EORTC QLQ-C30 physical functioning compared between study arms, where a high score for a functional scale represents a high/healthy level of functioning
|
8 years (after Last Patient Out (LPO))
|
Patient Reported Outcome Endpoint IV - global quality of life (QoL) score
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the standardized global health status/QoL score (based on the revised global health status/QoL QL2) as measured by EORTC QLQ-C30 summary score compared between study arms, where a high score for the global health status/QoL represents a high QoL.
|
8 years (after Last Patient Out (LPO))
|
Patient Reported Outcome Endpoint V - patient reported outcomes (fatigue, emotional functioning, physical functioning, global quality of life)
Time Frame: 8 years (after Last Patient Out (LPO))
|
Correlation of all patient reported outcomes explained above (fatigue, emotional functioning, physical functioning, global quality of life) with MET-hours
|
8 years (after Last Patient Out (LPO))
|
Body Composition Endpoint I - body mass index (BMI)
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the influence of BMI on DFS, RFS and OS
|
8 years (after Last Patient Out (LPO))
|
Body Composition Endpoint II - body fat
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the influence of body fat on DFS, RFS and OS
|
8 years (after Last Patient Out (LPO))
|
Body Composition Endpoint III - waist circumference
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the influence of waist circumference on DFS, RFS and OS
|
8 years (after Last Patient Out (LPO))
|
Cardiovascular Endpoint - cardiovascular complications
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the incidence of cardiovascular complications (myocardial infarction, stroke, newly diagnosed diabetes mellitus, newly diagnosed hypertension)
|
8 years (after Last Patient Out (LPO))
|
Safety Endpoint I - serious adverse events (SAEs)
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of the incidence of physical activity related SAEs and physical activity related deaths in both arms
|
8 years (after Last Patient Out (LPO))
|
Safety Endpoint II - time to SAEs
Time Frame: 8 years (after Last Patient Out (LPO))
|
Evaluation of time from study start to physical activity related SAEs
|
8 years (after Last Patient Out (LPO))
|
Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study)
Time Frame: 8 years (after Last Patient Out (LPO))
|
Correlation of molecular and biochemical markers with DFS, RFS, OS and with physical activity.
The analysis of molecular markers will depend on the markers which will be defined during the course of the study in addition to Insulin & ILGF.
|
8 years (after Last Patient Out (LPO))
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Josef Thaler, MD, Austrian Breast & Colorectal Cancer Study Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABCSG C08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Carcinoma
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal CarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingPembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Wuhan Union Hospital, ChinaNot yet recruitingRecurrent Colorectal Carcinoma | Advanced Colorectal CarcinomaChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Carcinoma | Colorectal Adenoma and CarcinomaNetherlands
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Center for Advancing Translational Sciences (NCATS)Not yet recruitingRecurrent Colorectal Carcinoma | Locally Advanced Colorectal Carcinoma | Stage III Colorectal CancerUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
Clinical Trials on endurance exercise
-
University of CincinnatiCompletedStroke, Ischemic | Dysphagia, Oral PhaseUnited States
-
Riphah International UniversityCompleted
-
Norwegian University of Science and TechnologyLHL-Klinikkene, Røros; LHL-Klinikkene, FeiringWithdrawnVentricular Dysfunction, Left | Heart Failure, DiastolicNorway
-
University of Illinois at Urbana-ChampaignNational Heart, Lung, and Blood Institute (NHLBI)CompletedVascular Health | Autonomic FunctionUnited States
-
Rigshospitalet, DenmarkCompleted
-
Charite University, Berlin, GermanyUnknown
-
University of TorontoCompleted
-
University of CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingIschemic Stroke | Dysphagia | Dysphagia, OropharyngealUnited States
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
Comenius UniversityUniversity of Roma La Sapienza; University of Primorska; University of Padova; Physiko-...Recruiting